Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy

James P. Bolling, MD; Roi Dagan, MD, MS; Michael Rutenberg, MD, PhD; Maria Mamalui-Hunter, PhD; Steven J. Buskirk, MD; Michael G. Heckman, MS; Alexander P. Hochwald; and Roelf Slopsema, MSc

Abstract

Objective: To review the current state of radiation therapy for uveal melanoma and compare particle radiation and brachytherapy.

Patients and Methods: The medical records of 156 patients treated for uveal melanoma between May 30, 2012, and March 16, 2020, were retrospectively reviewed. Treatments consisted of either radioactive iodine 125 implant (RAI) or fractionated proton radiation (proton beam therapy [PBT]). Baseline characteristics were compared using a Wilcoxon rank sum test or \( \chi^2 \) test. Outcomes were compared using Cox proportional hazards regression models or logistic regression models.

Results: The median length of follow-up after treatment was 2.7 years (range, 0.5 to 9.0 years). Patients who underwent treatment with RAI were older (median age, 67 vs 59 years; \( P < .001 \)) and had a lower tumor classification (American Joint Commission on Cancer; \( P = .001 \)) compared with those who underwent PBT. There was no significant difference between RAI and PBT in the outcomes of liver metastases, death, enucleation, tearing, vision loss, retinal detachment, tumor thickness, conjunctivitis, optic neuropathy, iris neovascularization, or neovascular glaucoma (all \( P > .05 \)). Patients who underwent RAI treatment had significantly higher risk of diplopia (\( P < .001 \)), cataract progression (\( P < .001 \)), and maculopathy (\( P = .03 \)) compared with those who received PBT. Patients who underwent RAI were at higher risk of eyelash loss (\( P = .006 \)) compared with the PBT group.

Conclusion: Treatment with PBT and RAI has similar efficacy; however, there are differences in the adverse outcomes associated with these 2 modalities.

ª 2021 THE AUTHORS. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Uveal melanoma (UM) is the most common form of noncutaneous melanoma, accounting for 5.5% of melanoma cases with a known primary tumor. Immunotherapy with checkpoint inhibition is minimally effective in the treatment of metastatic UM, and median survival for metastatic UM is less than 1 year. Survival is better in patients in whom UM is confined to the eye than in patients with metastatic UM. Treatment for primary UM is usually radiation or an enucleation surgical procedure. Laser treatment is reserved for very small tumors and most commonly involves a slow infrared laser to deliver a hyperthermia effect. External photon radiation has also been described. However, the most common treatment for UM is brachytherapy with an iodine 125, palladium 103, or ruthenium 106 implant. Although a multicenter randomized clinical trial of medium-size melanomas found no difference in survival for patients treated with a radioactive iodine 125 implant compared with enucleation, a large multicenter, nonrandomized, size-adjusted study found improved survival with a radioactive iodine 125 implant (RAI) compared with enucleation for UM.

Although RAI is the most common treatment for primary UM, proton beam therapy (PBT) is becoming increasingly common.
The medical literature reveals no difference in survival or incidence of metastasis with RAI vs PBT for treatment of UM. The purpose of this study was to review the status of radiation therapy for UM and to compare adverse outcomes associated with RAI vs PBT in the treatment of UM. By comparing these 2 radiation modalities, we hope to provide evidence-based understanding for the role of particle radiation in one cancer.

PATIENTS AND METHODS

Study Population
A total of 156 patients with UM treated at the Mayo Clinic in Florida between May 30, 2012, and March 16, 2020, were included in this retrospective study (92 PBT, 64 RAI). Two patients who were treated during this period were excluded from this analysis because they did not return for follow-up. Patients who received RAI were treated with a dose of 85 Gy radiobiological equivalent to the tumor apex according to the protocol used in the Collaborative Ocular Melanoma Study. This radiation dose was the standard brachytherapy protocol at Mayo Clinic during the study period and is consistent with recommendations of the American Brachytherapy Society. Figure 1 shows intraoperative ultrasonographic verification of RAI placement adjacent to the intraocular tumor. Patients treated with PBT were treated at the University of Florida Health Proton Therapy Institute with a dose of 60 Gy radiobiological equivalent in 4 consecutive fractions according to a previously described protocol. The dedicated eye line uses a high-energy, cyclotron-based proton therapy system. The energy at the entrance of the eye line is 105 MeV. A range modulator wheel generates the spread-out Bragg peak, while a variable range shifter system adjusts the range and spreads the beam laterally. Four tantalum buttons (T-rings; Mira Inc) were implanted to aid in tumor localization. Figure 2 shows surgical placement of tantalum markers with radiologic confirmation of marker locations.

Information was collected regarding baseline characteristics, including date of birth, Snellen visual acuity in each eye, cataract status in the tumor eye, macular status in the tumor eye, tumor thickness, tumor largest basal diameter, subretinal fluid, American Joint Committee on Cancer classification T score, date and nature of treatment, any associated extraocular muscle disinsertion, needle aspiration cytology results, and tumor gene expression profile (Table 1). Cytology and gene expression profile were not performed on all patients and only done when clinically indicated or requested by the patient. Outcomes were also recorded and included death, liver metastases, persistent diplopia (at least 3 months), epiphora, subsequent enucleation surgical procedure, visual acuity in each eye at each follow-up visit, presence of subretinal fluid at each follow-up visit, tumor thickness at each follow-up visit, presence of iris neovascularization at each follow-up visit, neovascular glaucoma diagnosed at each follow-up visit, cataract status in the treated eye at each follow-up visit, and optical coherence tomography consistent with macular edema at each follow-up visit in the treated eye.

Statistical Analyses
Continuous variables were summarized with the sample median and range. Categorical variables were summarized with number and percentage of patients. Comparisons of baseline characteristics between the proton beam and radioactive implant groups were made using a Wilcoxon rank sum test (continuous and ordinal variables) or a \( \chi^2 \) test (categorical variables). Comparisons of outcomes between the RAI and PBT groups were made using Cox proportional hazards regression models for
time-to-event outcomes (death, liver metastases, enucleation, disappearance of subretinal fluid, occurrence of 20/200 or worse visual acuity in patients with better than 20/200 visual acuity at baseline, occurrence of a 30% decrease in tumor thickness from baseline, progression of cataract, neovascularization of iris, neovascular glaucoma, and macular edema in patients without maculopathy at baseline). Logistic regression models were used for binary outcomes not dependent on follow-up length (persistent double vision, epiphora, and eyelash loss). Hazard ratios and 95% CIs were estimated for Cox regression models, while odds ratios and 95% CIs were estimated for logistic regression models. In Cox regression analysis, censoring occurred at the date of last known follow-up, death, liver metastases, enucleation, disappearance of subretinal fluid, occurrence of 20/200 or worse vision, and occurrence of a 30% decrease in tumor thickness from baseline. Unadjusted models were first assessed, followed by multivariable models that were adjusted for baseline characteristics that had the strongest difference (ie, lowest P value) between the RAI and PBT groups, allowing no more than 1 variable in the model for each 10 patients who experienced the given outcome per recommended guidelines.26

P<.05 was considered statistically significant, and all statistical tests were 2-sided. Statistical analysis was performed using R statistical software (version 3.6.2; R Foundation for Statistical Computing).

RESULTS

A comparison of baseline patient characteristics in the RAI and PBT groups is shown in Table 1. Compared with patients who underwent PBT, those who received RAI were older (median age, 67 vs 59 years; P<.001), had a lower pretreatment largest basal diameter (median, 11.1 vs 13.5 mm; P=.01), had a lower pretreatment tumor thickness (median, 3.8 vs 5.0 mm; P=.02), and had a less severe American Joint Committee on Cancer T class at presentation (P=.001). Outcomes are compared between the 2 treatment groups in Table 2. The median length of follow-up after treatment was 2.7 years (range, 0.5 to 9.0 years). Follow-up was not significantly different between the PBT group (median, 2.7 years; range, 0.5 to 9.0 years) and the RAI group (median, 2.5 years; range, 0.5 to 7.0 years) (P=.67).

In unadjusted analysis, patients who received RAI had a significantly higher risk of double vision (OR, 0.06; P<.001) and were significantly more likely to have muscle disinsertion during the surgical procedure (OR, 0.01; P<.001) compared with patients who underwent PBT. Patients who received RAI had a significantly lower likelihood of eyelash loss after radiation (P=.006; Figure 3) and were significantly more likely to have development of cataract during the follow-up period than patients in the PBT group (P=.001). Patients in the RAI group also had a significantly higher likelihood of a 30% decrease in tumor thickness from baseline adjusting for potential confounding variables (Table 2; P=.XX). No significant differences between RAI and PBT were observed regarding death, liver metastases, enucleation, disappearance of subretinal fluid, or occurrence of visual acuity of 20/200 or less (Table 2; all P>.05).

Several other pieces of information were also of interest. First, 29 patients had a fine-needle aspiration biopsy. Of these 29 patients, 23 (79.3%) were evaluated for genetic expression profile (Castle Biosciences, Inc); 10 (43.5%) were class 1A; 3 (13.0%) were class 1B; and 10 (43.5%) were class 2. Second, of the patients who had
development of liver metastases, survival at 1 year was 28.0% (95% CI, 14.3% to 55.0%) (6 of 21 patients). Third, there was a strong association between double vision and muscle disinserted ($P < .001$); of the 40 patients who had an extraocular muscle temporarily detached from the globe, 13 (32.5%) had double vision compared with 7 of 116 patients (6.0%) without muscle disinserted.

| Variable                              | Proton beam (N=92) | Radioactive implant (N=64) | $P$ value |
|---------------------------------------|--------------------|----------------------------|-----------|
| Age at treatment (y)                  | 59 (25-94)         | 67 (32-94)                 | <.001     |
| Male sex                              | 44 (47.8)          | 30 (46.9%)                 | .91       |
| Snellen visual acuity in affected eye |                    |                            | .19       |
| 20/20                                 | 18 (19.6)          | 6 (9.4)                    |           |
| 20/25                                 | 14 (15.2)          | 10 (15.6)                  |           |
| 20/30                                 | 10 (10.9)          | 7 (10.9)                   |           |
| 20/40                                 | 14 (15.2)          | 11 (17.2)                  |           |
| 20/50                                 | 8 (8.7)            | 10 (15.6)                  |           |
| 20/60                                 | 8 (8.7)            | 2 (3.1)                    |           |
| 20/70                                 | 3 (3.3)            | 3 (4.7)                    |           |
| 20/80                                 | 2 (2.2)            | 1 (1.6)                    |           |
| 20/100                                | 3 (3.3)            | 2 (3.1)                    |           |
| 20/200                                | 2 (2.2)            | 5 (7.8)                    |           |
| 20/400                                | 5 (5.4)            | 3 (4.7)                    |           |
| CF                                    | 1 (1.1)            | 2 (3.1)                    |           |
| HM                                    | 4 (4.3)            | 1 (1.6)                    |           |
| LP                                    | 0 (0.0)            | 1 (1.6)                    |           |
| NLP                                   | 0 (0.0)            | 0 (0.0)                    |           |
| Snellen visual acuity in unaffected eye|                  |                            | .006      |
| 20/20                                 | 52 (56.5)          | 20 (31.2)                  |           |
| 20/25                                 | 16 (17.4)          | 18 (28.1)                  |           |
| 20/30                                 | 12 (13.0)          | 11 (17.2)                  |           |
| 20/40                                 | 3 (3.3)            | 11 (17.2)                  |           |
| 20/50                                 | 1 (1.1)            | 2 (3.1)                    |           |
| 20/60                                 | 0 (0.0)            | 0 (0.0)                    |           |
| 20/70                                 | 2 (2.2)            | 0 (0.0)                    |           |
| 20/80                                 | 0 (0.0)            | 0 (0.0)                    |           |
| 20/100                                | 1 (1.1)            | 2 (3.1)                    |           |
| 20/200                                | 1 (1.1)            | 0 (0.0)                    |           |
| 20/400                                | 0 (0.0)            | 0 (0.0)                    |           |
| CF                                    | 1 (1.1)            | 0 (0.0)                    |           |
| HM                                    | 1 (1.1)            | 0 (0.0)                    |           |
| LP                                    | 1 (1.1)            | 0 (0.0)                    |           |
| NLP                                   | 1 (1.1)            | 0 (0.0)                    |           |
| Pretreatment largest basal diameter (mm) | 13.5 (4.7-22.0)   | 11.1 (5.0-17.1)            | .01       |
| Pretreatment thickness (mm)           | 5.0 (0.7-13.0)     | 3.8 (1.9-12.0)             | .02       |
| Subretinal fluid at presentation       | 85 (92.4)          | 52 (81.2)                  | .04       |
| AJCC presentation                      |                    |                            | .001      |
| T1                                    | 26 (28.3)          | 25 (39.1)                  |           |
| T2                                    | 21 (22.8)          | 24 (37.5)                  |           |
| T3                                    | 26 (28.3)          | 14 (21.9)                  |           |
| T4                                    | 19 (20.7)          | 1 (1.6)                    |           |

*AJCC, American Joint Committee on Cancer Classification; CF, count fingers; HM, hand motion; LP, light perception; NLP, no light perception.

**Data are presented as median (range) or No. (percentage) of patients.
| Outcome                                      | No. of patients | No. (%) of patients who experienced the outcome | Association measure | Unadjusted analysis | Multivariable analysis |
|----------------------------------------------|-----------------|-------------------------------------------------|---------------------|--------------------|------------------------|
|                                              |                 |                                                 |                     | Estimate (95% CI)   | P value                | Estimate (95% CI)   | P value                |
| Double vision                                |                 |                                                 | Odds ratio          |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 18 (28.1)                                       | 1.00 (Reference)    | 0.06 (0.009-0.21)  | <.001                  | 1.00 (Reference)    | 0.07 (0.01-0.25)       | <.001                  |
| Proton beam                                  | 92              | 2 (2.2)                                         |                     |                    |                        |                      |                        |
| Death                                        |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 15 (23.4)                                       | 1.00 (Reference)    | 1.16 (0.61-2.20)   | .66                    | 1.00 (Reference)    | 1.39 (0.65-3.0)        | .40                    |
| Proton beam                                  | 92              | 26 (28.3)                                       |                     |                    |                        |                      |                        |
| Liver metastases                             |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 9 (14.1)                                        | 1.00 (Reference)    | 1.46 (0.66-3.20)   | .35                    | 1.00 (Reference)    | 2.26 (0.96-5.31)       | .06                    |
| Proton beam                                  | 91              | 21 (23.1)                                       |                     |                    |                        |                      |                        |
| Epiphora                                     |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 1 (1.6)                                         | 1.00 (Reference)    | 5.67 (0.71-45.06)  | .10                    | 1.00 (Reference)    | NA                     | .13                    |
| Proton beam                                  | 91              | 12 (13.2)                                       |                     |                    |                        |                      |                        |
| Muscle disinserted                           |                 |                                                 | Odds ratio          |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 39 (60.9)                                       | 1.00 (Reference)    | 0.01 (<0.01-0.04)  | <.001                  | 1.00 (Reference)    | <0.01 (<0.01-0.02)    | <.001                  |
| Proton beam                                  | 92              | 1 (1.1)                                         |                     |                    |                        |                      |                        |
| Enucleation                                  |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 5 (7.8)                                         | 1.00 (Reference)    | 1.50 (0.45-5.02)   | .51                    | 1.00 (Reference)    | NA                     | .13                    |
| Proton beam                                  | 91              | 8 (8.8)                                         |                     |                    |                        |                      |                        |
| Disappearance of subretinal fluid in patients with subretinal fluid at baseline | | | Hazard ratio | | | | |
| Radioactive implant                          | 52              | 23 (44.2)                                       | 1.00 (Reference)    | 1.19 (0.71-1.98)   | .51                    | 1.00 (Reference)    | 0.80 (0.46-1.41)       | .44                    |
| Proton beam                                  | 84              | 41 (48.8)                                       |                     |                    |                        |                      |                        |
| Occurrence of 20/200 or worse visual acuity in patients with better than 20/200 visual acuity at baseline | | | Hazard ratio | | | | |
| Radioactive implant                          | 52              | 16 (30.8)                                       | 1.00 (Reference)    | 1.67 (0.92-3.01)   | .09                    | 1.00 (Reference)    | 1.50 (0.79-2.84)       | .21                    |
| Proton beam                                  | 79              | 36 (45.6)                                       |                     |                    |                        |                      |                        |
| Occurrence of a 30% decrease in tumor thickness from baseline | | | Hazard ratio | | | | |
| Radioactive implant                          | 64              | 55 (85.9)                                       | 1.00 (Reference)    | 0.63 (0.43-0.91)   | .01                    | 1.00 (Reference)    | 0.69 (0.45-1.05)       | .09                    |
| Proton beam                                  | 91              | 66 (72.5)                                       |                     |                    |                        |                      |                        |
| Eyelash loss                                 |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 2 (3.1)                                         | 1.00 (Reference)    | 7.11 (1.65-30.97)  | .008                   | 1.00 (Reference)    | 7.97 (1.79-35.42)      | .006                   |
| Proton beam                                  | 91              | 18 (19.8)                                       |                     |                    |                        |                      |                        |
| Keratoconjunctivitis                         |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 14 (21.9)                                       | 1.00 (Reference)    | 1.09 (0.55-2.15)   | .80                    | 1.00 (Reference)    | 1.06 (0.51-2.20)       | .88                    |
| Proton beam                                  | 91              | 21 (23.1)                                       |                     |                    |                        |                      |                        |
| Iris neovascularization                      |                 |                                                 | Hazard ratio        |                    |                        |                      |                        |
| Radioactive implant                          | 64              | 8 (12.5)                                        | 1.00 (Reference)    | 1.48 (0.63-3.47)   | .36                    | 1.00 (Reference)    | 2.00 (0.82-4.90)       | .13                    |
| Proton beam                                  | 91              | 16 (17.6)                                       |                     |                    |                        |                      |                        |
This study confirmed that UM can be lethal: 41 of 156 patients died from metastatic UM during the follow-up period, with median follow up of 2.7 years. This study was also designed to identify adverse outcomes associated with RAI and PBT.

By identifying adverse outcomes associated with a treatment, we may be able to avoid some complications by prescribing an alternative modality. For example, patients who received RAI were significantly more likely to have persistent diplopia. Furthermore, there was a strong association between muscle disinsertion and persistent double vision ($P<.001$).

Since we can predict which patients will need to have a muscle removed, we can reduce the incidence of double vision by treating those patients with PBT, which does not require muscle disinsertion when using previously described techniques.\textsuperscript{24} When performing an RAI operation, the extraocular muscles are temporarily disinserted when doing so is necessary to position the implant properly. A muscle must be temporarily detached from the outside of the globe if the tumor is located

### TABLE 2. Continued

| Outcome                                      | No. of patients | No. (%) of patients who experienced the outcome | Association measure | Unadjusted analysis | Multivariable analysis |
|----------------------------------------------|-----------------|-------------------------------------------------|---------------------|---------------------|------------------------|
|                                              |                 |                                                 |                     |                     |                        |
| Neovascular glaucoma                         |                 |                                                 |                     |                     |                        |
| Radioactive implant                          | 64              | 7 (10.9)                                        | Hazard ratio        | 1.00 (Reference)   | 1.00 (Reference)       |
| Proton beam                                  | 91              | 16 (17.6)                                       |                      | 1.67 (0.69-4.07)   | 2.11 (0.83-5.40)       |
| Cataract progression in patients without cataract operation at baseline |                 |                                                 |                     |                     |                        |
| Radioactive implant                          | 45              | 30 (66.7)                                       | Hazard ratio        | 1.00 (Reference)   | 1.00 (Reference)       |
| Proton beam                                  | 78              | 22 (28.2)                                       |                      | 0.29 (0.16-0.51)   | 0.20 (0.10-0.39)       |
| Maculopathy in patients without preexisting maculopathy at baseline |                 |                                                 |                     |                     |                        |
| Radioactive implant                          | 56              | 34 (60.7)                                       | Hazard ratio        | 1.00 (Reference)   | 1.00 (Reference)       |
| Proton beam                                  | 52              | 23 (44.2)                                       |                      | 0.56 (0.33-0.97)   | 0.52 (0.28-0.94)       |
| Optic neuropathy in patients without preexisting optic neuropathy at baseline |                 |                                                 |                     |                     |                        |
| Radioactive implant                          | 63              | 11 (17.5)                                       | Hazard ratio        | 1.00 (Reference)   | 1.00 (Reference)       |
| Proton beam                                  | 74              | 10 (13.5)                                       |                      | 0.71 (0.30-1.69)   | 0.77 (0.31-1.89)       |

\textsuperscript{a}AJCC, American Joint Committee on Cancer; NA, not applicable.
\textsuperscript{b}Odds ratios and 95% CIs result from logistic regression models. Hazard ratios and 95% CIs result from Cox proportional hazards regression models. Multivariable models were adjusted for baseline characteristics that showed the strongest difference between the radioactive implant and proton beam groups, allowing no more than 1 variable in the model for each 10 patients who experienced the given outcome. Specifically, models were adjusted for age at treatment (double vision, liver metastases, eyelash loss, iris neovascularization, neovascular glaucoma, optic neuropathy), age at treatment and AJCC class at presentation (death and keratoconjunctivitis), age at treatment, AJCC class at presentation, age at treatment, AJCC class at presentation, and Snellen visual acuity in unaffected eye (muscle disinserted), age at treatment, AJCC class at presentation, Snellen visual acuity in unaffected eye, pretreatment largest basal diameter, and pretreatment tumor thickness (disappearance of subretinal fluid), age at treatment, AJCC class at presentation, Snellen visual acuity in unaffected eye, and pretreatment largest basal diameter (occurrence of 20/200 or worse visual acuity, cataract progression, and maculopathy), and age at treatment, AJCC class at presentation, Snellen visual acuity in unaffected eye, pretreatment largest basal diameter, pretreatment tumor thickness, and subretinal fluid at presentation (occurrence of a 30% decrease in tumor thickness).

\textsuperscript{c}No multivariable analysis was performed for enucleation owing to the rare nature of this outcome.
immediately adjacent to the muscle insertion on the inside of the globe. It may also be necessary to detach a muscle if a tumor is located adjacent to the optic nerve in order to gain access to the part of the eyeball where the tumor is located.

In our patients, eyelash loss was significantly more likely in patients treated with PBT than RAI, as displayed in Figure 3. The likely reason for eyelash loss in these patients is due to the radiation of the eyelashes in patients with tumors that were located anterior to the equator of the eye. When anteriorly located tumors are treated with PBT, the eyelid typically receives 50% to 100% of the radiation dose. The eyelid gets less than 10% of the radiation dose when anterior tumors are treated with RAI. The reason that the eyelid receives less radiation with RAI in selected patients is because the implant used in this study (and shown in Figure 1) is shielded with a gold carrier that shields the eyelid from radiation in an anteriorly located tumor. The eyelid also gets less radiation with PBT when the tumor is located posterior to the equator due to the sharp fall off of particle radiation. Perhaps PBT should be avoided in patients with anterior tumors if eyelid deformity or ocular surface disease is a concern.

Since this study is not randomized, we know that the treatment groups are dissimilar in some respects. For example, the RAI group was older than the PBT group and for that reason likely had more age-related eye diseases such as cataract or maculopathy. In fact, that is exactly the case. Figure 4 shows that patients who received RAI were more likely to have development of cataract than patients who underwent PBT, and Figure 5 shows that patients in the RAI group were also more likely to have development of maculopathy.

The 2 treatment groups also differ in initial tumor size. Patients who underwent PBT in this study had larger tumors than those who received RAI. This finding may explain why RAI patients were more likely to have a 30% reduction in tumor thickness. A small tumor is more likely to flatten completely, while a large tumor often has a residual thickness.

The size of our study may not have enough power to detect some differences between the PBT and RAI groups. Therefore, the possibility of a type II error is important to consider (ie, a false-negative association). We therefore cannot draw conclusions about survival or the incidence of metastatic melanoma between patients treated with RAI and PBT. The literature, however, does not
document a difference in survival or the likelihood of liver metastases from UM in patients treated with RAI27-29 or PBT.30-33 Also, one randomized clinical trial compared helium ion radiation to radioactive iodine implant22 and found no significant difference in survival. The pertinent literature comparing RAI and PBT is summarized in a 2013 systematic review.21

The financial cost of PBT has been scrutinized.34-36 The cost of RAI, however, can also be significant since RAI includes 2 operations as opposed to 1. Enucleation is less costly than either RAI or PBT.37

FIGURE 4. Progression of cataract during the 3-year period after treatment in patients without cataract progression at baseline who were treated with radioactive iodine 125 implant (RAI) and proton radiation (proton beam therapy [PBT]). This analysis included only patients who did not have cataract or previous cataract operation at presentation.

FIGURE 5. Progression of maculopathy during the 3-year period after treatment in patients without maculopathy at baseline who were treated with radioactive iodine 125 implant (RAI) and proton radiation (proton beam therapy [PBT]). This analysis included only patients who did not have maculopathy at presentation.
Prognostic genetic testing can be performed on tumor tissue obtained by fine-needle aspiration biopsy. In our experience, needle biopsy for genetic testing can be included at the time of RAI placement or at the time of placement of fiducial markers for PBT.35-40

CONCLUSION

Patients with UM are at significant risk of dying from their disease. Radiation for treatment of primary UM may be delivered by RAI and PBT. In this study, RAI was associated with double vision and PBT was associated with eyelash loss. The utility of proton radiation for treatment of UM may be to reduce morbidity through careful patient selection.

ACKNOWLEDGMENTS

The authors would like to acknowledge the support of the Marco Family Foundation for support of this research including an unrestricted research grant to Mayo Clinic and for support of the University of Florida Health Proton Therapy Institute.

REFERENCES

1. Chang AE, Karnell LH, Mencer HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer. 1998;83(8):1664-1678.
2. McLaughlin CC, Wu X-C, Jemal A, Martin HJ, Ries LA, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005;105(10):1000-1007.
3. Yang J, Planson DK, Mars BP, Carvalho RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758834018751775.
4. Rantala ES, Hemberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561-568.
5. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241-257.
6. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(6):989-998.
7. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881-1885.
8. Singh AD, Kivelä T, Seregard S, Robertson D, Beno JF. Primary transpupillary thermotherapy of “small” choroidal melanoma: is it safe? Br J Ophthalmol. 2008;92(6):727-728.
9. Shields JA, Shields CL. Current management of posterior uveal melanoma. Mayo Clin Proc. 1993;68(12):196-1200.
10. Széki D, Curr C, Paulsen F, Kaulich T, Bartz-Schmidt KU. Endoresection with adjuvant ruthenium brachytherapy for selected uveal melanoma patients—the Tuebingen experience. Acta Ophthalmol. 2017;95(8):e727-e733.
11. Gündüz K, Bechrakis NE. Exoresection and endoresection for uveal melanoma. Middle East Afr J Ophthalmol. 2010;17(3):210-216.
12. Kowsky D, Robertson JC, Woodfin M, et al. Systematic review and meta-analysis on the use of photon-based stereotactic radiosurgery versus fractionated stereotactic radiotherapy for the treatment of uveal melanoma. Am J Clin Oncol. 2021;44(1):32-42.
13. Pagliara MM, Tagliferni L, Azzario L, et al. Ruthenium brachytherapy for uveal melanomas: factors affecting the development of radiation complications. Brachytherapy. 2018;17(2):432-438.
14. Maheshwari A, Fingr PT. Regression patterns of choroidal melanoma: after palladium-103 (103Pd) plaque brachytherapy. Eur J Ophthalmol. 2018;28(6):722-730.
15. Jiang P, Purtschwaridze K, Kandzia G, et al. 106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma. Retic Oncol. 2020;15(1):183.
16. Diener-West M, Earle JD, Fine SL, et al. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings; COMS Report No. 18. Arch Ophthalmol. 2001;119(7):969-982.
17. Messer JA, Zuhour RJ, Haque W, et al. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. J Contemp Brachytherapy. 2020;12(4):303-310.
18. Breweingto BY, Shao YF, Davidson HF, Cebulla CM. Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol. 2018;12:925-934.
19. Damarla B. Managing patients with choroidal melanoma in the COVID-19 era: a personal perspective [editorial]. Br J Ophthalmol. 2020;104(7):885-886.
20. Nathan P, Cohen V, Coupland S, et al. United Kingdom Uveal Melanoma Guideline Development Working Group. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2404-2412.
21. Wang Z, Nabhun M, Schild SE, et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86(1):18-26.
22. Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma: a prospective, randomized, dynamically balanced trial. Ophthalmology. 1993;100(10):1547-1554.
23. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study; COMS Report No. 3. Control Clin Trials. 1993;14(5):362-391.
24. Slopesma RL, Mamanlai M, Bolling J, et al. Can CT imaging improve targeting accuracy in clip-based proton therapy of ocular melanomas? Phys Med Biol. 2017;64(3):035010.
25. Gragoudas ES, Gotein M, Koehler AH, et al. Proton radiation of small choroidal malignant melanomas. Am J Ophthalmol. 1977;83(5):665-673.
26. LaVange LM, Stearns SC, Lafata JE, Koch GG, Shah BV. Innovative strategies using SUDAAN for analysis of health surveys with complex samples. Stat Methods Med Res. 1996;5(3):311-329.

27. Echegaray JJ, Beshrakis NE, Singh N, Bellerive C, Singh AD. Iodine-125 brachytherapy for uveal melanoma: a systematic review of radiation dose. Ocul Oncol Pathol. 2017;3(3):193-198.

28. Binder C, Mruthyunjaya P, Scheffer AC, et al. Practice patterns for the treatment of uveal melanoma with iodine-125 plaque brachytherapy: Ocular Oncology Study Consortium Report 5. Ocul Oncol Pathol. 2020;6(3):210-218.

29. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219-1228.

30. Gragoudas ES, Lane AM, Regan S, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118(6):773-778.

31. Desjardins L, Lumbroso-Le Rauç L, Levy-Gabriel C, et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthamlc Res. 2006;38(5):255-260.

32. Lane AM, Kim IK, Gragoudas ES. Long-term risk of melanoma-related mortality for patients with uveal melanoma treated with proton beam therapy. JAMA Ophthalmol. 2015;133(7):792-796.

33. Maschi C, Thariat J, Herault J, Caujolle J-P. Tumour response in uveal melanomas treated with proton beam therapy, Clin Oncol (R Coll Radiol). 2016;28(3):198-203.

34. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122(10):1483-1501.

35. Li G, Qiu B, Huang Y-X, et al. Cost-effectiveness analysis of proton beam therapy for treatment decision making in para-nasal sinus and nasal cavity cancers in China. BMC Cancer. 2020;20(1):599.

36. Schroeck FR, Jacobs BL, Bhayani SB, Nguyen PL, Penson D, Hu J. Cost of new technologies in prostate cancer treatment: systematic review of costs and cost effectiveness of robotic-assisted laparoscopic prostatectomy, intensity-modulated radiotherapy, and proton beam therapy. Eur Urol. 2017;72(5):712-735.

37. Moriarty JP, Borah BJ, Foote RL, Pulido JS, Shah ND. Cost-effectiveness of proton beam therapy for intraocular melanoma. PloS One. 2015;10(5):e0127814.

38. Seider MI, Mruthyunjaya P. Molecular prognostics for uveal melanoma. Retina. 2018;38(2):211-219.

39. Cai L, Paez-Escamilla M, Walter SD, et al. Gene expression profiling and PRAME status versus Tumor-Node-Metastasis staging for prognostication in uveal melanoma. Am J Ophthalmol. 2018;195:154-160.

40. Berry D, Seider M, Stinnett S, Mruthyunjaya P, Scheffer AC; Ocular Oncology Study Consortium. Relationship of clinical features and baseline tumor size with gene expression profile status in uveal melanoma: a multi-institutional study. Retina. 2019;39(6):1154-1164.